Maternal Exposures to COVID-19 Vaccine and Adverse Birth Outcomes: National Population Study (vol 40, e63, 2025)

초록

To the Editor: The authors regret that there were errors in Tables. This notice corrects Tables 1-3. Content of correction: Table 1. Demographic and clinical characteristics of pregnant women with COVID-19 vaccination during pregnancy and their matched control, the Korea Disease Control and Prevention Agency-COVID19-National Health Insurance Service cohort data (Table Presented.) Values are presented as number(%). The Seoul capital area refers to Seoul, Incheon, and Gyeonggi Provinces located in northwestern South Korea. COVID-19 = coronavirus disease 2019, 1Q = 1st quartile, 2Q = 2nd quartile, 3Q = 3rd quartile, 4Q = 4th quartile, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. aP values were from Mantel-Haenszel χ2 test. Table 2. Incidence and adjusted ORs of preterm birth and congenital malformation in the pregnant women who received any coronavirus disease 2019 vaccines during pregnancy and in their 1:4 matched control (Table Presented.) OR = odds ratio, CI = confidence interval. aAdjusted for women’s age, residential area (Seoul capital area or not), employment, income, disability, month of conception, pre-pregnancy obesity and smoking, and SARS-CoV-2 infection prior to pregnancy. Table 3. Incidence and adjusted ORs of preterm birth and congenital malformation in the pregnant women who received the mRNA-1273 or the NVX-CoV2373 and their 1:4 matched controls received the BNT162b2 during pregnancy (Table Presented.) OR = odds ratio, CI = confidence interval. aAdjusted for women’s age, residential area (Seoul capital area or not), employment, income, disability, month of conception, pre-pregnancy obesity and smoking, and SARS-CoV-2 infection prior to pregnancy. © 2025 Elsevier B.V., All rights reserved.

키워드